MEDIA ADVISORY --- BIO 2001: Highlight of Events for Tuesday, June 26
June 26, 2001
| 7 - 8:00 a.m. Plenary Breakfast Ballroom 6 |
Vernon Ellis, International Chairman and Managing Partner, Accenture, CEO/COO of International Pharmaceutical Company Michael Jackson, Global Discovery, Johnson & Johnson Bill Rastetter, Chief Executive Officer, IDEC
|
| 8:15 - 9:45 a.m. Finance Track Session Upper Level, Room 11 |
Sell-Side Analysts: A 2001 Roundup, this annual BIO panel will be chaired by Ray Dittamore, Managing Partner, Ernst & Young LLP, and will feature a number of well-known biotech analysts who will share their views on where the industry has been and where it's going.
|
| 8:15 - 9:45 a.m. Clinical/Regulatory Upper Level, Room 1B |
Developing AIDS Drugs for the New Millennium, chaired by David W. Barry M.D., Chairman and CEO, Triangle Pharmaceuticals, Inc., this session discusses how companies can navigate regulation and competition to produce and market new drugs to fight HIV.
|
| 8:15 - 9:45 a.m. Upper Level, Room 10 Upper Level, Room 11 |
Apoptosis-Based Therapies, recent insights into cell death mechanisms are revealing strategies for development of new pharmaceuticals and other types of therapeutic strategies for combating defective apoptosis regulation during disease.
|
| 8:15 - 9:45 a.m. Sales/Marketing Session Mezzanine Level, Room 14B |
How will the Biotechnology Revolution Affect the Current U.S. Health Care Supply System, Marsha K. Millonig, MBA, R.Ph., Vice President, Health Care Distribution Management Association Health Care Foundation will chair a discussion of whether 98 pipeline entities studied by HDMA will enhance, replace or compete with products already on the market and how they will affect the health care system.
|
| 8:15 - 9:45 a.m. Science Track Session Upper Level, Room 9 |
Converting the Human Genome into Therapeutics: from Genes to Drugs, a panel chaired by Dr. Stan Watson, MHIR University of Michigan, will discuss strategies to accelerate the drug development process now that the sequencing of the human genome has provided thousands of new but unvalidated targets.
|
| 8:15 - 11:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
Safety and Regulatory Oversight of Novel Crops Symposium: A Public Discussion, chaired by Terry Medley, Vice President, Global Regulatory Affairs, DuPont Biosolutions Enterprise, U.S. government representatives will present their views on the comprehensive nature of their oversight, communication with the public and mechanisms for public input to their decision-making.
|
| 9:30 a.m. Press Conference Upper Level, Room 5B |
Viaken Systems Press Briefing, Viaken Systems closes $13 million in second round financing. Sterling Venture Partners leads round, including Allianz, MacAndrews & Forbes and returning investors, Core Capital and Mid-Atlantic Venture Funds.
|
| 10 a.m. Press Conference Upper Level, Room 5B |
Question and Answer Session with Dr. Walter Seufert, President, Envir Safety and Energy Division, BASF. (This session immediately follows Dr. Seufert.'s symposium on Convention Manufacturing and Chemical Waster Generation Can the Marriage of Chemistry and Biotechnology Bring Solutions? which is held in Upper Level Room 3.
|
| 10:15 - 11:45 a.m. Clinical Regulatory Track Upper Level, Room 1B |
Bringing Genetic Medicine into the Mainstream, Presentations will bring participants up-to-date on attempts to define analytic and clinic validity for testing of mutations in several model genes; the steps needed to ensure that evolving technologies receive proper attention by the organizations that establish billing codes, fees and reimbursement; and patenting, licensing and regulation of new technologies. The activities of the U.S. Department of Health and Human Services Secretary's Advisory Committee on Genetic Testing (SACGT) will also be reported in this session chaired by Edward R.B. McCabe, M.D., Ph.D., Chair, Department of Pediatrics, UCLA, and Chair, SACGT, UCLA School of Medicine.
|
| 10:15 - 11:45 a.m. Science Track Session Upper Level, Room 10 |
Biotechnology at the National Laboratories, Co-chairs Reinhold Mann, Life Sciences Division Director, Oak Ridge National Laboratory and F. Blaine Metting, Ph.D., Fundamental Sciences Division, Pacific Northwest National Laboratory will provide an overview of biotechnology research at the U.S. Department of Energy national laboratories.
|
|
12 - 1:45 p.m. |
Dr. Florence Wambugu, Director, ISSA AfriCenter, Kenya Cameron Marley, patient
|
|
2 - 3:00 p.m. |
Planting the Future Through Space, C. Blake Power, Director of Outreach, NASA Space Product Development Program, chairs a panel on how companies are using space and microgravity in their food and agriculture-related research.
|
|
2 - 3:30 p.m. |
Optimizing Genes and Proteins with Directed Evolution Technologies, this panel will discuss the field of directed evolution as it applies to human therapeutics, agriculture and industrial enzymes.
|
|
2 - 3:30 p.m. |
The Future of DNA Microarrays and Bioinformatics in Research and Diagnostics, chaired by August Sick, Senior Manager, Business Development, Invitrogen Corporation, this session will present recent applications demonstrating the power of microarrays and advanced bioinformatics technologies in identifying differentially expressed biomarker genes.
|
|
2 - 3:30 p.m. |
Oversight of Gene Therapy: Protecting Patients and Promoting Research The FDA and NIH have recently formally issued plans that would dramatically change the regulatory environment for companies doing gene therapy experiments. This program, chaired by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss several important issues surrounding regulation in the industry.
|
|
2 - 5:30 p.m. |
Mergers & Acquisitions Symposium, chaired by Richard A. Leavitt, Principal, William Gallagher Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller Ehrman White & McAuliffe LLP, speakers on this panel will address the future of genomics and the information challenge it poses.
|
|
3 p.m. |
Florence Wambugu, Ph.D., Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from Kenya."
|
|
4 p.m. |
MediChem/Neurocrine Announcement, MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical discovery and development company, will announce that they have entered into a two-year collaborative GPCR agreement in proteomics for new drug development.
|
|
4 - 5:30 p.m. |
Animal, Mineral or Vegetable: Which Model for Product Discovery, John A. Ryals, Ph.D., President and CEO, Paradigm Genetics, chairs a discussion about the utility of different gene-based discovery models that have influenced the success of the genomics industry.
|
|
4 - 5:30 p.m. |
The Impact of State Drug Price Control Schemes on Emerging Biotech Companies, Thomas C. Norton, Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion of the consequences of state drug price control programs.
|
|
4 - 5:30 p.m. |
Managing Diabetes: Advances in Insulin Therapy from Novel Delivery Systems, Lars Karlsen, Senior Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S, chairs a discussion of how recent advances in insulin delivery will improve patient compliance with insulin regimens and quality of life.
|
|
4 - 5:30 p.m. |
Raiders of the Lost Genome: Gene Analysis on the Post-Genome Era, chaired by Teresa W. Ayers, CEO and Director, Genomica, this panel will review and discuss a variety of new technologies that will facilitate the deciphering of genetic data and provide gene function information for product development.
|
|
4 - 5:30 p.m. |
Accepting New Technology: Media and Public Perception of Risks and Benefits, Linda Thrane, Executive Director, Council for Biotechnology Information, and other experts from the fields of risk communication, consumer research and the media will provide insight and guidance.
|
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Receive our newsletter from BIOtechNOW
